Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study
Our data suggest that LT4 therapy in older individuals with SCH is associated with a trade-off between the potentially beneficial effect on CV risk and the deleterious relationship with bone health and mortality risk. These risks need to be considered, mitigated, and discussed when LT4 therapy is being deliberated in older patients with SCH.
Authors
- Ian Maxwell
- Scott Wilkes (ORCID: https://orcid.org/0000-0003-2949-7711)
- Rosie Dew (ORCID: https://orcid.org/0000-0001-8428-1724)
- Mia Holley (ORCID: https://orcid.org/0000-0002-9522-6314)
- Salman Razvi (ORCID: https://orcid.org/0000-0002-9047-1556)
Institutions
- Clinical Research Institute (US)
- University of Sunderland (GB)
- University of Newcastle Australia (AU)
- Newcastle University (GB)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1210/clinem/dgaf208
- Citations
- 6
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 7.77